The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
Abstract
The continual reassessment method (CRM) is a popular dose-finding design for phase I clinical trials. This method requires that practitioners prespecify the toxicity probability at each dose. Such prespecification can be arbitrary, and different specifications of toxicity probabilities may lead to very different design properties. To overcome the arbitrariness and further enhance the robustness of the design, we propose using multiple parallel CRM models, each with a different set of prespecified toxicity probabilities. In the Bayesian paradigm, we assign a discrete probability mass to each CRM model as the prior model probability. The posterior probabilities of toxicity can be estimated by the Bayesian model averaging (BMA) approach. Dose escalation or deescalation is determined by comparing the target toxicity rate and the BMA estimates of the dose toxicity probabilities. We examine the properties of the BMA-CRM approach through extensive simulation studies, and also compare this new method and its variants with the original CRM. The results demonstrate that our BMA-CRM is competitive and robust, and eliminates the arbitrariness of the prespecification of toxicity probabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoeting, J. A., Madigan, D., Raftery, A. E., & Volinsky, C. T. (1999) · Statistical Science · doi:10.1214/ss/1009212519 · Cited by 4,118 · cited 1×
“…of these skeletons, we take a BMA approach to average π̂j across the CRM models to obtain the BMA estimate of the toxicity probability for dose level j. BMA is known to provide a better predictive performance than any single model (Raftery, Madigan, and Hoeting 1997; Hoeting et al. 1999).”
Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's Window
Madigan, D., & Raftery, A. E. (1994) · Journal of the American Statistical Association · doi:10.1080/01621459.1994.10476894 · Cited by 1,205 · cited 1×
“Madigan and Raftery (1994) noted that by averaging over all of the considered models, we can provide a better average predictive ability than can be attained using any single model based on a logarithm scoring rule.”
Method
Cited by
Bayesian Model Averaging: A Systematic Review and Conceptual Classification
Fragoso, T. M., Bertoli, W., & Louzada, F. (2018) · International Statistical Review · doi:10.1111/insr.12243 · Cited by 284
Metadata
- Authors
- Yin, G., & Yuan, Y.
- Venue
- Journal of the American Statistical Association
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 104
- Issue
- 487
- Pages
- 954-968
- ISSN
- 0162-1459 (ISSN-L)
- 1537-274X
- OpenAlex
- W2000705046
- Cited by
- 168
- References
- 2
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. https://app.cochat.ai/papers/10.1198/jasa.2009.ap08425
- The paper
- Yin, G., & Yuan, Y. (2009). Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Journal of the American Statistical Association. https://doi.org/10.1198/jasa.2009.ap08425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.